JP2017529059A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017529059A5 JP2017529059A5 JP2016576027A JP2016576027A JP2017529059A5 JP 2017529059 A5 JP2017529059 A5 JP 2017529059A5 JP 2016576027 A JP2016576027 A JP 2016576027A JP 2016576027 A JP2016576027 A JP 2016576027A JP 2017529059 A5 JP2017529059 A5 JP 2017529059A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- seq
- modified
- dimer
- modified gdf15
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims description 68
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 68
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 68
- 239000000539 dimer Substances 0.000 claims description 26
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 claims description 21
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 claims description 21
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 19
- 150000001413 amino acids Chemical class 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 108010071390 Serum Albumin Proteins 0.000 claims description 9
- 102000007562 Serum Albumin Human genes 0.000 claims description 9
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 208000018914 glucose metabolism disease Diseases 0.000 claims description 7
- 102220005382 rs33914470 Human genes 0.000 claims description 6
- 102220143003 rs753997345 Human genes 0.000 claims description 6
- 102220025225 rs199476363 Human genes 0.000 claims description 5
- 102220123860 rs61760902 Human genes 0.000 claims description 5
- 238000006467 substitution reaction Methods 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 102220353134 c.68G>A Human genes 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 239000013598 vector Substances 0.000 claims description 4
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 102200078418 rs1805085 Human genes 0.000 claims description 3
- 102220503690 GTP-binding protein REM 1_T94N_mutation Human genes 0.000 claims description 2
- 230000037396 body weight Effects 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 239000000710 homodimer Substances 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 102200150805 rs1057519492 Human genes 0.000 claims description 2
- 102220230165 rs1064793071 Human genes 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 102200090880 rs28933100 Human genes 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 description 17
- 102000037865 fusion proteins Human genes 0.000 description 17
- 229940024606 amino acid Drugs 0.000 description 15
- 108010076504 Protein Sorting Signals Proteins 0.000 description 7
- 102220058798 rs786202903 Human genes 0.000 description 4
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 3
- 230000004988 N-glycosylation Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 102200075235 rs118204106 Human genes 0.000 description 1
- 102220248744 rs145985140 Human genes 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462031063P | 2014-07-30 | 2014-07-30 | |
| US62/031,063 | 2014-07-30 | ||
| US201562195908P | 2015-07-23 | 2015-07-23 | |
| US62/195,908 | 2015-07-23 | ||
| PCT/US2015/042510 WO2016018931A1 (en) | 2014-07-30 | 2015-07-28 | Compositions and methods of use for treating metabolic disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017529059A JP2017529059A (ja) | 2017-10-05 |
| JP2017529059A5 true JP2017529059A5 (enExample) | 2018-09-06 |
| JP6704358B2 JP6704358B2 (ja) | 2020-06-03 |
Family
ID=55179329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016576027A Active JP6704358B2 (ja) | 2014-07-30 | 2015-07-28 | 代謝障害を治療するための組成物および使用方法 |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US9834586B2 (enExample) |
| EP (1) | EP3174894B1 (enExample) |
| JP (1) | JP6704358B2 (enExample) |
| KR (1) | KR20170065026A (enExample) |
| CN (1) | CN106573966B (enExample) |
| AP (1) | AP2016009663A0 (enExample) |
| AU (1) | AU2015296640B2 (enExample) |
| CA (1) | CA2953827A1 (enExample) |
| CL (1) | CL2017000201A1 (enExample) |
| CO (1) | CO2017000614A2 (enExample) |
| CR (1) | CR20170027A (enExample) |
| DO (1) | DOP2017000025A (enExample) |
| EA (1) | EA035581B1 (enExample) |
| EC (1) | ECSP17005276A (enExample) |
| ES (1) | ES2883158T3 (enExample) |
| IL (1) | IL249793B (enExample) |
| MD (1) | MD20170020A2 (enExample) |
| MX (1) | MX370115B (enExample) |
| MY (1) | MY192917A (enExample) |
| PE (1) | PE20170771A1 (enExample) |
| PH (1) | PH12017500153A1 (enExample) |
| SG (2) | SG10201802098UA (enExample) |
| SV (1) | SV2017005367A (enExample) |
| TN (1) | TN2016000578A1 (enExample) |
| TW (1) | TWI710570B (enExample) |
| UA (1) | UA123432C2 (enExample) |
| WO (1) | WO2016018931A1 (enExample) |
| ZA (1) | ZA201700311B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014018575A2 (pt) | 2012-01-26 | 2017-07-04 | Amgen Inc | polipetídeos de fator de diferenciação de crescimento 15 (gdf-15) |
| JP6254146B2 (ja) | 2012-03-27 | 2017-12-27 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | 代謝障害を治療するための組成物および方法 |
| KR101993714B1 (ko) | 2013-01-30 | 2019-06-28 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | 대사 장애를 치료하는데 이용하기 위한 조성물과 방법 |
| US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
| WO2015117024A1 (en) | 2014-01-31 | 2015-08-06 | Mayo Foundation For Medical Education And Research | Novel therapeutics for the treatment of glaucoma |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| CR20170027A (es) | 2014-07-30 | 2017-05-09 | Ngm Biopharmaceuticals Inc | Composiciones y métodos de uso para tratar trastornos metabólicos |
| PL3212226T3 (pl) | 2014-10-31 | 2020-11-02 | Ngm Biopharmaceuticals, Inc. | Kompozycje i sposoby stosowania w leczeniu zaburzeń metabolicznych |
| CA3016035A1 (en) | 2016-03-31 | 2017-10-05 | Ngm Biopharmaceuticals, Inc. | Binding proteins and methods of use thereof |
| US10336812B2 (en) | 2016-05-10 | 2019-07-02 | Janssen Biotech, Inc. | GDF15 fusion proteins and uses thereof |
| PE20190117A1 (es) | 2016-05-24 | 2019-01-16 | Novo Nordisk As | Compuestos de mic-1 y usos de estos |
| EP3522911B1 (en) * | 2016-10-07 | 2021-12-08 | Beth Israel Deaconess Medical Center, Inc. | Compositions comprising relaxin and methods of use thereof |
| JOP20190097A1 (ar) | 2016-10-27 | 2019-04-28 | Janssen Pharmaceutica Nv | الجلوبولينات المناعية واستخداماتها |
| CN110770251A (zh) * | 2017-04-20 | 2020-02-07 | 诺和诺德股份有限公司 | 纯化白蛋白融合蛋白的方法 |
| US11260108B2 (en) | 2017-09-10 | 2022-03-01 | Novo Nordisk A/S | MIC-1 and GLP-1 for use in the treatment of obesity |
| US11267863B2 (en) | 2018-01-19 | 2022-03-08 | Pepgene Inc. | N-terminal fusion partner for producing recombinant polypeptide, and method for producing recombinant polypeptide using same |
| TWI724392B (zh) | 2018-04-06 | 2021-04-11 | 美商美國禮來大藥廠 | 生長分化因子15促效劑化合物及其使用方法 |
| MA52205A (fr) | 2018-04-09 | 2021-02-17 | Amgen Inc | Protéines de fusion du facteur de différenciation de croissance 15 |
| AU2019317813A1 (en) | 2018-08-10 | 2021-02-11 | Novartis Ag | GFRAL extracellular domains and methods of use |
| US11590161B2 (en) | 2018-08-13 | 2023-02-28 | Viscera Labs, Inc. | Therapeutic composition and methods |
| US11524029B2 (en) | 2018-08-13 | 2022-12-13 | Viscera Labs, Inc. | Therapeutic composition and methods |
| CN119751697A (zh) | 2018-10-22 | 2025-04-04 | 詹森药业有限公司 | 胰高血糖素样肽1（glp1）-生长分化因子15（gdf15）融合蛋白及其用途 |
| EP4028413A1 (en) | 2019-09-10 | 2022-07-20 | Obsidian Therapeutics, Inc. | Ca2-il15 fusion proteins for tunable regulation |
| WO2021067655A1 (en) | 2019-10-04 | 2021-04-08 | Amgen Inc. | Use of gdf15 for treating cardiometabolic syndrome and other conditions |
| CN114729020A (zh) * | 2019-11-26 | 2022-07-08 | 株式会社柳韩洋行 | 长效gdf15融合蛋白及包含其的药物组合物 |
| JP7655619B2 (ja) * | 2019-12-11 | 2025-04-02 | エルジー・ケム・リミテッド | Ｏ－グリコシル化可能なポリペプチド領域およびｇｄｆ１５を含む融合ポリペプチド |
| EP4072543A4 (en) * | 2019-12-12 | 2024-02-07 | Qlaris Bio, Inc. | CONTROLLED RELEASE CROMAKALIM PRODRUGS |
| EP4085077A4 (en) | 2019-12-31 | 2024-01-17 | Beijing QL Biopharmaceutical Co., Ltd. | Fusion proteins of glp-1 and gdf15 and conjugates thereof |
| WO2023154953A1 (en) | 2022-02-14 | 2023-08-17 | Ngm Biopharmaceuticals, Inc. | Gdf15 polypeptides for treating and preventing autoimmune diseases |
Family Cites Families (107)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5194596A (en) * | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
| FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
| US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
| US5288931A (en) * | 1991-12-06 | 1994-02-22 | Genentech, Inc. | Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| WO1994003599A1 (fr) | 1992-08-04 | 1994-02-17 | Sagami Chemical Research Center | ADNc HUMAIN ET PROTEINE POUR LAQUELLE CODE CET ADNc |
| US6180602B1 (en) | 1992-08-04 | 2001-01-30 | Sagami Chemical Research Center | Human novel cDNA, TGF-beta superfamily protein encoded thereby and the use of immunosuppressive agent |
| JPH07250688A (ja) | 1994-01-28 | 1995-10-03 | Sagami Chem Res Center | ＴＧＦ−βスーパーファミリー蛋白質をコードするヒト新規ｃＤＮＡ |
| JPH07258293A (ja) | 1994-03-23 | 1995-10-09 | Asahi Chem Ind Co Ltd | 新規な蛋白質ならびにその製造方法 |
| AU1830195A (en) | 1994-12-15 | 1996-07-03 | Human Genome Sciences, Inc. | Prostatic growth factor |
| US5994102A (en) | 1994-12-15 | 1999-11-30 | Human Genome Sciences, Inc. | Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides |
| US6521227B1 (en) | 1999-11-18 | 2003-02-18 | Peter L. Hudson | Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| ES2324433T3 (es) | 1995-06-22 | 2009-08-06 | St Vincent's Hospital Sydney Limited | Tgf-beta novedoso similar a citocina. |
| US6524802B1 (en) | 1996-03-29 | 2003-02-25 | The Johns Hopkins University School Of Medicine | Methods of detecting growth differentiation factor-14 |
| NZ334592A (en) | 1996-09-11 | 2000-10-27 | Ortho Mcneil Pharm Inc | Protein growth factor related to TNF-beta and coupled with a toxic moiety for use in treating prostate cancer |
| WO1999006445A1 (en) | 1997-07-31 | 1999-02-11 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-15 |
| JP2003526322A (ja) | 1998-07-23 | 2003-09-09 | スミスクライン ビーチャム コーポレーション | 分泌型システインリッチタンパク質−６（ｓｃｒｐ−６） |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6465181B2 (en) | 1999-03-25 | 2002-10-15 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the prostate |
| US6974684B2 (en) | 2001-08-08 | 2005-12-13 | Curagen Corporation | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| ES2275513T3 (es) | 1999-05-17 | 2007-06-16 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Und Zum Vertrieb Von Pharmaka Mbh | Propiedades neuroprotectoras de gdf-15, un miembro de la superfamilia de tgf-beta. |
| GB9912350D0 (en) * | 1999-05-26 | 1999-07-28 | European Molecular Biology Lab Embl | Modified cytokine |
| RS50743B (sr) * | 2000-03-22 | 2010-08-31 | OCTAPHARMA BIOPHARMACEUTICALS GmbH. | Proizvodnja rekombinantnih faktora koagulacije krvi u humanim ćelijama |
| AU2001264563A1 (en) | 2000-04-12 | 2001-10-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US7514221B2 (en) | 2000-04-20 | 2009-04-07 | St. Vincent's Hospital Sydney Limited | Diagnostic assay and method of treatment involving macrophage inhibitory cytokine-1 (MIC-1) |
| WO2002020759A2 (en) | 2000-09-08 | 2002-03-14 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties |
| EP1354042A2 (en) | 2000-12-29 | 2003-10-22 | Curagen Corporation | Proteins and nucleic acids encoding same |
| TW200526779A (en) | 2001-02-08 | 2005-08-16 | Wyeth Corp | Modified and stabilized GDF propeptides and uses thereof |
| EP1395605B8 (en) | 2001-03-09 | 2014-12-17 | Iterative Therapeutics, Inc. | Polymeric immunoglobulin fusion proteins that target low-affinity fcgamma receptors |
| JP4516719B2 (ja) | 2001-05-11 | 2010-08-04 | アムジエン・インコーポレーテツド | Ｔａｌｌ−１と結合するペプチド及び関連分子 |
| GB0115195D0 (en) | 2001-06-21 | 2001-08-15 | Bae Systems Plc | Split-pin drill jig |
| FI117667B (fi) * | 2001-07-05 | 2007-01-15 | Univ Zuerich | Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä |
| US20030053431A1 (en) | 2001-09-10 | 2003-03-20 | Lila Madour | Method for performing handoff in a radio telecommunications network |
| US20060253913A1 (en) | 2001-12-21 | 2006-11-09 | Yue-Jin Huang | Production of hSA-linked butyrylcholinesterases in transgenic mammals |
| ES2545090T3 (es) | 2001-12-21 | 2015-09-08 | Human Genome Sciences, Inc. | Proteínas de fusión de albúmina y GCSF |
| US7919084B2 (en) | 2002-06-17 | 2011-04-05 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
| CA2390820A1 (en) | 2002-06-17 | 2003-12-17 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
| CN1241946C (zh) | 2002-07-01 | 2006-02-15 | 美国福源集团 | 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白 |
| CA2504508A1 (en) | 2002-11-08 | 2004-05-27 | Barnes-Jewish Hospital | Methods and compositions for prostate epithelial cell differentiation |
| US7348004B2 (en) | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
| ES2518865T3 (es) | 2004-04-13 | 2014-11-05 | St Vincent's Hospital Sydney Limited | Agente de inhibición de MIC-1 |
| WO2005113585A2 (en) | 2004-05-20 | 2005-12-01 | Acceleron Pharma Inc. | Modified tgf-beta superfamily polypeptides |
| US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| RU2401842C2 (ru) | 2004-10-08 | 2010-10-20 | Домантис Лимитед | Антагонисты и способы их применения |
| CA2595902C (en) | 2005-01-24 | 2017-08-22 | Pepscan Systems B.V. | Binding compounds, immunogenic compounds and peptidomimetics of the beta-3 hairpin loop of cystine-knot growth factors |
| JP2007258293A (ja) | 2006-03-22 | 2007-10-04 | Fuji Electric Holdings Co Ltd | はんだ濡れ性評価装置およびはんだ濡れ性評価方法 |
| DK2004683T3 (en) | 2006-03-24 | 2016-08-22 | Biogen Hemophilia Inc | PC5 AS A FACTOR IX PROPEPTID PROCESSING ENZYM |
| US8974748B2 (en) | 2007-04-05 | 2015-03-10 | Corning Incorporated | Dual inlet microchannel device and method for using same |
| EP2377876A1 (en) | 2006-06-02 | 2011-10-19 | Wyeth LLC | Use of proteins and peptides of the TGF-BETA superfamily for purification and therapeutic methods |
| US7754689B2 (en) | 2006-06-02 | 2010-07-13 | Wyeth Llc | Finger-1 peptide analogs of the TGF-β superfamily |
| US20100322945A1 (en) | 2006-07-26 | 2010-12-23 | Peter Timmerman | Immunogenic compounds and protein mimics |
| WO2008015254A2 (en) | 2006-08-04 | 2008-02-07 | Medizinische Hochschule Hannover | Means and methods for assessing the risk of cardiac interventions based on gdf-15 |
| ES2400282T3 (es) | 2007-04-25 | 2013-04-08 | Stem Cells Spin S.A. | Nueva línea de células madre y su aplicación |
| BRPI0814465B1 (pt) | 2007-07-26 | 2021-11-23 | Novagen Holding Corporation | Proteína de fusão, dímero, método para produzir uma proteína de fusão, linhagem de célula, usos de uma proteína de fusão e de uma composição farmacêutica e composição farmacêutica |
| AU2008281913B2 (en) | 2007-07-31 | 2013-11-07 | Affibody Ab | New albumin binding compositions, methods and uses |
| JP2010536717A (ja) | 2007-08-16 | 2010-12-02 | セントビンセンツ ホスピタル シドニー リミテッド | マクロファージ阻害性サイトカイン（ｍｉｃ−１）活性を調節するための作用物質及び方法 |
| US20100266707A1 (en) | 2007-10-09 | 2010-10-21 | Samuel Norbert Breit | Method of treating cachexia with the removal or inactivation of macrophage inhibitory cytokine-1 |
| ES2543985T3 (es) | 2007-10-22 | 2015-08-26 | St Vincent's Hospital Sydney Limited | Métodos de pronóstico |
| EP2207798A2 (en) * | 2007-10-29 | 2010-07-21 | Virginia Tech Intellectual Properties, Inc. | Porcine dc-sign, icam-3 and lsectin and uses thereof |
| PL2235064T3 (pl) | 2008-01-07 | 2016-06-30 | Amgen Inc | Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych |
| EP2242505A4 (en) | 2008-01-08 | 2012-03-07 | Biogenerix Ag | GLYCOCONJUGATION OF POLYPEPTIDES USING OLIGOSACCHARYLTRANSFERASES |
| EP2227696A1 (en) | 2008-01-08 | 2010-09-15 | Roche Diagnostics GmbH | Means and methods for assessing the risk of patients presenting to emergency units based on gdf-15 |
| EA018471B1 (ru) * | 2008-03-31 | 2013-08-30 | Глаксо Груп Лимитед | Слитые конструкции и конъюгаты лекарственного средства |
| WO2009141357A1 (en) | 2008-05-20 | 2009-11-26 | Roche Diagnostics Gmbh | Gdf-15 as biomarker in type 1 diabetes |
| EP2318844A1 (en) | 2008-07-14 | 2011-05-11 | Roche Diagnostics GmbH | Multimarker panel for diagnosing, monitoring and selecting the therapy for patients with heart failure |
| WO2010019263A2 (en) | 2008-08-15 | 2010-02-18 | Genzyme Corporation | Soluble flt constructs for treating cancers |
| MX349178B (es) | 2008-10-31 | 2017-07-17 | Centocor Ortho Biotech Inc | Diferenciación de células madre embrionarias humanas al linaje endocrino pancreático. |
| JP5444363B2 (ja) | 2008-10-31 | 2014-03-19 | セントビンセンツ ホスピタル シドニー リミテッド | 慢性腎疾患における予後判定の方法 |
| EP2209003A1 (en) | 2009-01-16 | 2010-07-21 | F. Hoffmann-Roche AG | Means and methods for differentiating between fibrosis and cirrhosis |
| EP2211182A1 (en) | 2009-01-16 | 2010-07-28 | Roche Diagnostics GmbH | Method for the assessment of severity of liver cirrhosis |
| CN102369016A (zh) | 2009-02-12 | 2012-03-07 | 史赛克公司 | 用于治疗系统性病症和疾病的包含TGF-β超家族成员的蛋白质的外周施用 |
| GB0902737D0 (en) | 2009-02-19 | 2009-04-01 | Univ Gent | GDF15 as a differential marker for spondyloarthropathy |
| KR101558642B1 (ko) | 2009-02-24 | 2015-10-12 | 솔크 인스티튜트 포 바이올로지칼 스터디즈 | Ｔｇｆ-베타 슈퍼패밀리의 설계자 리간드 |
| MY156542A (en) | 2009-05-05 | 2016-02-26 | Amgen Inc | Fgf21 mutants and uses thereof |
| MX2011013455A (es) | 2009-07-08 | 2012-02-13 | Amgen Inc | Diseño de moleculas de fc de anticuerpo estables y libres de agregacion a traves del diseño de la interfase del dominio de ch3. |
| WO2011008956A2 (en) | 2009-07-15 | 2011-01-20 | Zirus, Inc. | Mammalian genes involved in infection |
| US20120309697A1 (en) | 2009-10-28 | 2012-12-06 | Samuel Norbert Breit | Methods of diagnosing and prognosing colonic polyps |
| WO2011057120A1 (en) | 2009-11-05 | 2011-05-12 | Genentech, Inc. | Methods and composition for secretion of heterologous polypeptides |
| WO2011064758A2 (en) | 2009-11-30 | 2011-06-03 | Pfizer Limited | Fusion protein |
| JP5784624B2 (ja) | 2009-11-30 | 2015-09-24 | ヤンセン バイオテツク，インコーポレーテツド | 除去されたエフェクター機能を伴う抗体Ｆｃ突然変異 |
| US9212221B2 (en) | 2010-03-03 | 2015-12-15 | Detroit R & D, Inc. | Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses |
| JP5791335B2 (ja) | 2010-04-07 | 2015-10-07 | 花王株式会社 | オルガノポリシロキサン化合物の製造方法 |
| WO2011127458A2 (en) | 2010-04-09 | 2011-10-13 | University Of Southern California | Systems and methods of cell activated, controlled release delivery of growth factors for tissue repair and regeneration |
| EP2383571A1 (en) | 2010-05-02 | 2011-11-02 | Prof. Hess Medical Consulting GmbH | Growth differntioation factor 15 (GDF 15) for risk prediction of diabetic foot ulcer |
| CN103080746B (zh) | 2010-08-26 | 2015-07-15 | 弗·哈夫曼-拉罗切有限公司 | 生物标志物在评估从动脉高血压向心力衰竭的早期转变中的用途 |
| EP2439535A1 (en) | 2010-10-07 | 2012-04-11 | F. Hoffmann-La Roche AG | Diagnosis of diabetes related heart disease and GDF-15 and Troponin as predictors for the development of type 2 diabetes mellitus |
| US9732143B2 (en) * | 2011-02-03 | 2017-08-15 | Xoma Technology Ltd. | Methods and materials for enhancing functional protein expression in bacteria |
| WO2012138919A2 (en) | 2011-04-08 | 2012-10-11 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
| EP2697257B1 (en) | 2011-04-13 | 2016-10-19 | Bristol-Myers Squibb Company | Fc fusion proteins comprising novel linkers or arrangements |
| TW201306866A (zh) | 2011-06-30 | 2013-02-16 | Genentech Inc | 抗－ｃ－ｍｅｔ抗體調配物 |
| WO2013002362A1 (ja) | 2011-06-30 | 2013-01-03 | 中外製薬株式会社 | ヘテロ二量化ポリペプチド |
| BR112014018575A2 (pt) | 2012-01-26 | 2017-07-04 | Amgen Inc | polipetídeos de fator de diferenciação de crescimento 15 (gdf-15) |
| JP6254146B2 (ja) | 2012-03-27 | 2017-12-27 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | 代謝障害を治療するための組成物および方法 |
| WO2013192388A1 (en) | 2012-06-20 | 2013-12-27 | University Of Virginia Patent Foundation | Compositions and methods for regulating glucose homeostasis and insulin action |
| WO2014000042A1 (en) | 2012-06-27 | 2014-01-03 | Prince Henry's Institute Of Medical Research | COMPOSITIONS AND METHODS FOR MODIFYING TGF-β FAMILY LIGANDS |
| CA2876285A1 (en) | 2012-08-08 | 2014-02-13 | Roche Glycart Ag | Interleukin-10 fusion proteins and uses thereof |
| WO2014100689A1 (en) | 2012-12-21 | 2014-06-26 | Aveo Pharmaceuticals, Inc. | Anti-gdf15 antibodies |
| US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
| KR101993714B1 (ko) | 2013-01-30 | 2019-06-28 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | 대사 장애를 치료하는데 이용하기 위한 조성물과 방법 |
| BR112015023140A8 (pt) | 2013-03-15 | 2018-01-23 | Genentech Inc | proteínas de fusão, método para a fabricação da proteína de fusão, composições, ácido nucleico,vetor, célula hospedeira, métodos de produção de uma proteína de fusão, de tratamento da doença inflamatória intestinal, de inibição da infecção microbiana, de tratamento da lesão renal, para acelerar ou melhorar a cicatrização, para a prevenção ou tratamento de uma condição cardiovascular, para tratamento da síndrome metabólica e para tratamento da endotoxemia. |
| CN203123206U (zh) * | 2013-04-01 | 2013-08-14 | 宋艳丽 | 一种简易式一次性防污染无菌注射器 |
| EP3027642B1 (en) | 2013-07-31 | 2020-08-19 | Amgen Inc. | Growth differentiation factor 15 (gdf-15) constructs |
| KR20160034404A (ko) | 2013-07-31 | 2016-03-29 | 암젠 인크 | Ｆc-함유 폴리펩타이드의 안정화 |
| CR20170027A (es) | 2014-07-30 | 2017-05-09 | Ngm Biopharmaceuticals Inc | Composiciones y métodos de uso para tratar trastornos metabólicos |
| PL3212226T3 (pl) | 2014-10-31 | 2020-11-02 | Ngm Biopharmaceuticals, Inc. | Kompozycje i sposoby stosowania w leczeniu zaburzeń metabolicznych |
| US20190000923A1 (en) | 2015-12-22 | 2019-01-03 | Novartis Ag | Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
-
2015
- 2015-07-28 CR CR20170027A patent/CR20170027A/es unknown
- 2015-07-28 TW TW104124401A patent/TWI710570B/zh active
- 2015-07-28 SG SG10201802098UA patent/SG10201802098UA/en unknown
- 2015-07-28 CA CA2953827A patent/CA2953827A1/en active Pending
- 2015-07-28 MY MYPI2017700310A patent/MY192917A/en unknown
- 2015-07-28 ES ES15827485T patent/ES2883158T3/es active Active
- 2015-07-28 PE PE2017000103A patent/PE20170771A1/es unknown
- 2015-07-28 MD MDA20170020A patent/MD20170020A2/ro not_active Application Discontinuation
- 2015-07-28 KR KR1020177002592A patent/KR20170065026A/ko not_active Withdrawn
- 2015-07-28 TN TN2016000578A patent/TN2016000578A1/en unknown
- 2015-07-28 SG SG11201700378PA patent/SG11201700378PA/en unknown
- 2015-07-28 US US14/811,578 patent/US9834586B2/en not_active Expired - Fee Related
- 2015-07-28 WO PCT/US2015/042510 patent/WO2016018931A1/en not_active Ceased
- 2015-07-28 CN CN201580041716.9A patent/CN106573966B/zh active Active
- 2015-07-28 EP EP15827485.2A patent/EP3174894B1/en active Active
- 2015-07-28 JP JP2016576027A patent/JP6704358B2/ja active Active
- 2015-07-28 UA UAA201700670A patent/UA123432C2/uk unknown
- 2015-07-28 EA EA201692477A patent/EA035581B1/ru unknown
- 2015-07-28 AP AP2016009663A patent/AP2016009663A0/en unknown
- 2015-07-28 MX MX2017000964A patent/MX370115B/es active IP Right Grant
- 2015-07-28 AU AU2015296640A patent/AU2015296640B2/en active Active
-
2016
- 2016-12-27 IL IL249793A patent/IL249793B/en unknown
-
2017
- 2017-01-13 ZA ZA2017/00311A patent/ZA201700311B/en unknown
- 2017-01-24 PH PH12017500153A patent/PH12017500153A1/en unknown
- 2017-01-25 CO CONC2017/0000614A patent/CO2017000614A2/es unknown
- 2017-01-25 CL CL2017000201A patent/CL2017000201A1/es unknown
- 2017-01-25 EC ECIEPI20175276A patent/ECSP17005276A/es unknown
- 2017-01-25 DO DO2017000025A patent/DOP2017000025A/es unknown
- 2017-01-25 SV SV2017005367A patent/SV2017005367A/es unknown
- 2017-11-01 US US15/801,198 patent/US20180134761A1/en not_active Abandoned
-
2020
- 2020-02-07 US US16/784,877 patent/US11358995B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017529059A5 (enExample) | ||
| US12173060B2 (en) | Compositions and methods of use for treating metabolic disorders | |
| JP2016511752A5 (enExample) | ||
| CN105980400B (zh) | 生长分化因子15(gdf-15)构建体 | |
| CN102781960B (zh) | Hsa相关组合物及使用方法 | |
| CN106573966B (zh) | 用于治疗代谢异常的组合物和方法 | |
| CN102625811B (zh) | Fgf21突变体及其用途 | |
| JP5801807B2 (ja) | 修飾された血管作動性腸管ペプチド | |
| EP2585098B1 (en) | Fzd8 extracellular domains and fzd8 extracellular domain fusion molecules for use in treating obesity and obesity-related disorders | |
| JP2017538395A5 (enExample) | ||
| RU2015136440A (ru) | Композиции и способы применения для лечения метаболических расстройств | |
| KR20020026558A (ko) | 키메라성 폴리펩타이드, 이의 제조 방법 및 용도 | |
| JP2022523972A (ja) | 増殖分化因子１５併用療法 | |
| JP2019527053A (ja) | 可溶性線維芽細胞成長因子受容体３（ｓＦＧＦＲ３）ポリペプチドおよびその使用 | |
| JP2022118184A (ja) | コンジュゲートされたｃ１エステラーゼインヒビター及びその使用 | |
| JP2020509737A5 (enExample) | ||
| CA3000697A1 (en) | Treatment of bile acid disorders | |
| JP2009510999A (ja) | キメラ治療剤 | |
| CN106279430B (zh) | Exendin‑4类似物融合蛋白及其制备方法和用途 | |
| KR20250166188A (ko) | Tnfr2 결합 폴리펩타이드 및 이의 용도의 방법 | |
| CN109400711B (zh) | 一种PDGFRβ靶向性肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途 | |
| CN113874393A (zh) | 对hbv包膜蛋白具有特异性的结合分子 | |
| CN117186239A (zh) | 融合蛋白及其应用 | |
| JP7681684B2 (ja) | 成長ホルモン融合タンパク質及びその調製方法並びに使用 | |
| JP2024537239A (ja) | インターロイキン－１０ムテイン及びその融合タンパク質 |